[1] Lammert F, Gurusamy K, Ko CW, et al. Gallstones. Nat Rev Dis Primers, 2016, 2:16024. [2] Gutt C, Schläfer S, Lammert F. The treatment of gallstone disease. Dtsch Arztebl Int, 2020, 117(9):148-158. [3] Shabanzadeh DM. The symptomatic outcomes of cholecystectomy for gallstones. J Clin Med, 2023, 12(5):1897. [4] 吴正东, 徐刚, 慕海峰, 等. LC联合ERCP和EST治疗胆囊结石合并肝外胆管结石患者疗效研究. 实用肝脏病杂志, 2023, 26(3): 432-435. [5] Su Z, Gong Y, Liang Z. Prevalence of gallstone in Mainland China: A meta-analysis of cross-sectional studies. Clin Res Hepatol Gastroenterol, 2020, 44(4):e69-e71. [6] Chen LY, Qiao QH, Zhang SC, et al. Metabolic syndrome and gallstone disease. World J Gastroenterol, 2012, 18(31):4215-4220. [7] Lyu J, Lin Q, Fang Z, et al. Complex impacts of gallstone disease on metabolic syndrome and nonalcoholic fatty liver disease. Front Endocrinol (Lausanne), 2022, 13:1032557. [8] Stender S, Nordestgaard BG, Tybjaerg-Hansen A. Elevated body mass index as a causal risk factor for symptomatic gallstone disease: a Mendelian randomization study. Hepatology, 2013, 58(6):2133-2141. [9] 许建, 路翔宇, 龚军, 等. 老年体检人群代谢综合征和新发胆石症检出率调查. 实用肝脏病杂志, 2019, 22(1): 133-136. [10] Cirillo DJ, Wallace RB, Rodabough RJ, et al. Effect of estrogen therapy on gallbladder disease. JAMA, 2005, 293(3):330-339. [11] Galyani Moghaddam T, Fakheri H. The incidence and outcome of pregnancy-related biliary sludge/stones and potential risk factors. Arch Iran Med, 2013, 16(1):12-16. [12] Zhang M, Mao M, Zhang C, et al. Blood lipid metabolism and the risk of gallstone disease: a multi-center study and meta-analysis. Lipids Health Dis, 2022, 21(1):26. [13] Wang F, Wang J, Li Y, et al. Gallstone disease and type 2 diabetes risk: A Mendelian randomization study. Hepatology, 2019, 70(2):610-620. [14] Chen JY, Hsu CT, Liu JH, et al. Clinical predictors of incident gallstone disease in a Chinese population in Taipei, Taiwan. BMC Gastroenterol, 2014, 14:83. [15] Patel AH, Peddu D, Amin S, et al. Nonalcoholic fatty liver disease in lean/nonobese and obese individuals: a comprehensive review on prevalence, pathogenesis, clinical outcomes, and treatment. J Clin Transl Hepatol, 2023, 11(2):502-515. [16] Chrysavgis L, Ztriva E, Protopapas A, et al. Nonalcoholic fatty liver disease in lean subjects: prognosis, outcomes and management. World J Gastroenterol, 2020, 26(42):6514-6528. [17] Jang H, Kim W. Non-obese or lean nonalcoholic fatty liver disease matters, but is it preventable or inevitable in light of its risk factors? Clin Mol Hepatol. 2023, 29(2):381-383. [18] Kim Y, Han E, Lee JS, et al. Cardiovascular risk is elevated in lean subjects with nonalcoholic fatty liver disease. Gut Liver, 2022, 16(2):290-299. [19] Yang SH, Yoon J, Lee YJ, et al. Lipid accumulation product index predicts new-onset type 2 diabetes among non-obese Koreans: a 12-Year longitudinal study. Diabetes Metab Syndr Obes, 2022, 15:3729-3737. [20] Gao N, Deng J, Wang J, et al. The prevalence, comorbidities, influencing factors, and identifying factors of non-obese fatty liver disease. Front Med (Lausanne), 2022, 9:1038475. |